Hear more messages of support for CEPI's upcoming third strategic cycle here.

"The 100 Days Mission reflects our shared commitment to deliver faster, safer and more effective preparedness and response for all countries."

A powerful message of support for CEPI 3.0 and the 100 Days Mission from Indonesia's Minister of Health, Budi Sadikin ⬇️

Richard Hatchett, epidemiólogo: “El riesgo de que haya una pandemia es hoy mayor que en 2019” El director ejecutivo de la Coalición para las Innovaciones en Preparación ante Epidemias advierte del peligro de la inteligencia artificial y el biodiseño para la salud global y aboga por dialogar e ...

CEPI CEO Richard Hatchett sets out why pandemic preparedness remains a global priority.

From the growing threat of emerging diseases, including the potential misuse of AI, to declining investment in public health, the risks are evolving. At the same time, the tools to respond are improving.

More ⬇️

Beyond the lab for the 100 Days Mission What does it take to achieve the 100 Days Mission—a goal to deliver new vaccines within 100 days of a pandemic threat being identified? Increasingly, the answer lies beyond the lab. At CEPI’s Asia-Pac...

Our March newsletter has just landed 🗞️

This month zooms in on how regulatory preparedness will be a crucial enabler of the 100 Days Mission. It also features all the regular updates, including CEPI 3.0 campaign progress, our latest R&D partnerships and plenty more.

Late last year, CEPI, @path.org and Africa CDC convened 80+ experts from 20 countries in Nairobi to move RPECA from concept to a concrete roadmap that establishes a regionally owned ecosystem for rapid clinical trials and real-world evidence generation.

Discover the key takeaways: bit.ly/4rVQopT

📣Positive topline results from a CEPI-supported study of Bavarian Nordic's Mpox vaccine in 2-to-11-year-olds have been submitted to the European Medicines Agency, paving the way for the jab to be approved for use in younger age groups: www.bavarian-nordic.com/investor/new...

Securing the Future CEPI 3.0 – our 2027-2031 strategy – aims to transform the world’s ability to tackle epidemic and pandemic threats. Explore CEPI’s 3.0 Investment Case to see how we can #SecureTheFuture together.

This systems-level approach closely aligns with CEPI’s 3.0 Strategy, which will strengthen the global capabilities needed to operationalise the 100 Days Mission so that vaccines can be deployed quickly and equitably in response to future threats.

The authors explain that the #100DaysMission is possible, but rapid vaccine manufacturing at scale relies on an ecosystem of enablers, from robust governance and secure supply chains to “warm” manufacturing capacity that can be activated at speed.

The 100 Days Mission: a perspective on accelerating vaccine manufacturing for future pandemics - BMC Global and Public Health The “100 Days Mission” aims to compress the timeline for delivering safe and effective vaccines in response to future pandemics. Here, we present insights from Pfizer leaders involved in the COVID-19 ...

A new Springer Nature perspective featuring @Pfizer leaders explores how to make the 100 Days Mission a reality.

Read the full article: link.springer.com/article/10.1...

CEPI 3.0 and the Race to Develop the World’s First Lassa Fever Vaccine - Nigeria Health Watch Shalom David and Uwaifiokun Okhuarobo (Lead writers) Every dry season, the wards begin to fill. At Irrua Specialist Teaching Hospital in Edo...

Strengthening capabilities needed to advance a Lassa fever vaccine are also the same capabilities needed to ensure any vaccine can be developed, whether that’s for a known disease like Lassa fever or a future Disease X.

This approach sits at the heart of CEPI 3.0 and the 100 Days Mission. More ⬇

From ambition to action: Turning CEPI’s strategy into tangible impact Discover how CEPI's strategy makes a real-world difference

The 100 Days Mission is the benchmark for pandemic preparedness, but achieving it requires more than scientific breakthroughs. It requires a shift from individual vaccines to building the broad capabilities needed for rapid response.

More in our new blog ⬇️

Dr Richard Hatchett, CEPI CEO, said: “This collaboration... exemplifies the power of pairing scientific innovation with world-class manufacturing capabilities. Together, we are strengthening the ecosystem needed to rapidly develop, produce and deliver vaccines in response to future Nipah outbreaks"

Under the agreement, SII has been granted a non-exclusive, worldwide licence in the field of Nipah virus vaccines, enabling the company to support the development, manufacture and potential future supply of the vaccine candidate developed at the University of Oxford.

Oxford and Serum Institute of India sign IP license agreement to The University of Oxford and Serum Institute of India Pvt. Ltd. (SII), a Cyrus Poonawalla Group company and the world’s largest vaccine manufacturer, have signed an Intellectual Property license

The University of Oxford and Serum Institute of India have signed an IP licensing agreement to advance development and manufacturing of the CEPI-funded ChAdOx1 NipahB vaccine candidate - an important step toward strengthening global preparedness against Nipah virus.

And we’re pleased to share that one project is already underway with IZSAM. Over 12 months, IZSAM, together with UKHSA, RIVM, NICD and BRMI, will work with 14 CEPI network members across 12 countries to strengthen biorisk management in line with ISO 35001.

These collaborations will support implementation of ISO 35001 standards, as well as laboratory design and infrastructure improvements, training, policy dialogue, and stakeholder engagement, helping to ensure that the science behind the 100 Days Mission is conducted safely and securely.

Fondation Mérieux / Mérieux Foundation USA, African Society for Laboratory Medicine (ASLM), AFMS- Air Filter Maintenance Services (AFMS), and Brown University Pandemic Center.

The new biosecurity partners are Istituto Zooprofilattico Sperimentale Abruzzo e Molise "G. Caporale"​ (IZSAM), Biorisk Management International (BRMI), National Institute for Communicable Diseases (NICD), European Research Infrastructure on Highly Pathogenic Agents (ERINHA)...

CEPI strengthens global biosecurity with eight new partnerships ⬇️

The partnerships will help advance our biosecurity work. Selected through a competitive Request for Proposals, these organisations are global leaders in training, policy, laboratory infrastructure, and biorisk management.

CEPI 3.0 Champions Throughout 2026, we’re capturing voices of support from across our Coalition, highlighting why continued investment in CEPI is crucial for securing a future against epidemics and pandemic threats.

.@AfricaCDC has been a longstanding partner of CEPI, and its ongoing support as we begin the CEPI 3.0 Strategy (2027-2031) will be crucial for its success.

Hear from more voices of support here: vimeo.com/showcase/121...

"The 100 Days Mission is a game-changer" - H.E Dr Jean Kaseya, Director General, Africa CDC.

In this supportive statement from Africa CDC, Dr Kaseya explains how CEPI's 100 Days Mission is helping the continent to #SecureTheFuture against the threat of epidemics and pandemics.

"In less than 10 years, CEPI has helped to redefine how the world develops vaccines for emerging infectious diseases, shifting from reactive crisis response to collaborative preparedness." - Dr Tedros Adhanom Ghebreyesus.

A powerful endorsement of CEPI 3.0 from our @who.int partners.

CEPI 3.0: Securing the future against epidemic and pandemic threats This month marked a major step forward in the global fight against epidemics and pandemics with the launch of the CEPI 3.0 Investment Case and Strategy.

Our February newsletter is live! It spotlights the launch of CEPI 3.0 Investment Case and Strategy.

Inside, you’ll find a deep dive into our next strategic phase, messages of support, a dedicated reading corner and more.

A great video from our partners on the impact that CEPI's funding is having on clinical trial preparedness in the West Africa region ⬇️

Infographic titled 'Snapshot of CEPI 3.0' displaying a circular flowchart divided into three sections: Integrated viral family approach to vaccine development; Ready-to-activate networks and capabilities; Vaccine platforms are ready and available. Central text reads: 'Impact: Saving lives quickly, reducing risk, and making innovation accessible.'

Epidemics & pandemics are a defining #HealthSecurity challenge of our time. @cepi.net is working to transform the way we tackle today’s viral threats and get ahead of tomorrow’s.

CEPI's 3.0 strategy aims to secure a safer, better prepared future for all: https://bit.ly/4cFE2y9

#SecureTheFuture

PATH and CEPI team members are seated in a conference room for a simulation exercise to test the design and development of the Biospecimen Sourcing Initiative. Overlaid text reads: "With help from PATH, CEPI’s Biospecimen Sourcing Initiative aims to create a faster, easier, more equitable system for collecting biological samples in an outbreak"

The Biospecimen Sourcing Initiative aims to facilitate the timely and ethical collection of biological samples during an outbreak: https://bit.ly/4qILZWZ

Biospecimens from survivors are necessary for the rapid development of new vaccines, treatments & diagnostics.

#100DaysMission @cepi.net

CEPI backs updated Zaire ebolavirus vaccine that aims to improve vaccine affordability and accessibility $30 million to update manufacturing process and make a vaccine intended to be less costly to produce and easier to deploy.

The article spotlights CEPI’s partnership with MSD and Hilleman Laboratories to update the licensed Zaire Ebola vaccine to overcome these challenges, supporting greater vaccine self-reliance in Africa and helping establish 100 Days Mission capabilities.

Yet Ebola and other filoviruses continue to emerge each year, with outbreaks disproportionately affecting countries across Africa.

Barriers to vaccine access remain, such as ultra-cold chain requirements, limited manufacturing scalability and affordability challenges for countries at highest risk.

Over the past decade, collaboration has helped shift Ebola from a global health emergency to a disease that can be more easily contained. Access to licensed vaccines has truly changed the trajectory of outbreaks.

Africa: Ebola Has Gone From a Global Emergency to a Disease We Can Stop, Says CEPI Chief "In a single decade, the world has transformed Ebola from a global emergency to a disease that can be stopped in its tracks," said Dr Richard Hatchett, CEO of the Coalition for Epidemic Preparedness I...

A new All Africa feature highlights both the progress made against Ebola — and the work still ahead — drawing on insights from CEPI CEO Richard Hatchett.